Daclizumab and Alemtuzumab as Induction Agents in Adult Intestinal and Multivisceral Transplantation: Rejection and Infection Rates in 40 Recipients During the Early Postoperative Period
To access this article, please choose from the options below
PII: S0041-1345(09)01775-8
doi:10.1016/j.transproceed.2009.12.019
© 2010 Published by Elsevier Inc.
